View
213
Download
0
Category
Tags:
Preview:
DESCRIPTION
A basic powerpoint presentation to help freshers or interested folks understand what is clinical research all about
Citation preview
Mr.Siva Kartheek Matam M.PharmPatient Safety SpecialistMumbai
Any research conducted on humans with ethical values to show that a device, drug, or treatment method is safe and effective.
It is a process of taking a new drug molecule in to the market through the regulatory approvals.
1937 – Elixir Sulfanilamide disaster
105 US citizens died after treatment with sulfanilamide elixir containing diethylene glycol (DEG)
The incident hastened final enactment in 1938 of the Federal Food, Drug and Cosmetic Act
1950’s - Thalidomide tragedy
Prescribed for controlling nausea and vomiting in pregnant women
Teratogenic – children born with deformed limbs.
1962 – Ban of thalidomide use in pregnant women.
PHASE I: Objective:
Objective of Phase 1 studies is to determine the maximum-tolerated dose with well-defined potential toxicities Initial assessment of safety, drug tolerability, and dose range in humans To study pharmacokinetic and pharmacodynamic parameters of the drug in human beings Healthy volunteers Small subject population (20-80)
PHASE II: Objective:
Objective of Phase 2 Studies is to define the dose regimen of the drug that elicits the desired therapeutic benefit and that outweighs the observed clinical risks
Initial assessment of efficacy (proof-of-concept) and further assessment of safety
Involve patients who have the indicated disease or condition
Small patient population (100-300)
PHASE III: Objective:
To provide sufficient data to convince the regulatory authorities of the favourable benefit/risk ratio of the drug under investigation
Large-scale studies aimed at verifying efficacy establishing safety, and establishing the optimum dosage
Phase-3 studies also called as confirmatory studies
Involve a larger number of patients (1000-3000)
Protocol Investigator’s Brochure (IB) Form 1572 (FDA) – Statement by
Investigator Undertaking by Investigator (CDSCO –
ScheduleY) Financial Disclosure form Ethical Committee approval Directorate General for Foreign Trade
(DGFT) approval
Informed Consent Form (ICF) Source Documents Case Report Form (CRF) Serious Adverse Event (SAE) Reporting
form Investigator Trial File (ITF) Correspondence file
Filing NDA
(New Drug Applications) at
FDA
POST MARKETING SURVEILLANCE (PMS): Objective:
To assess the long term effects of the drug
To determine drug behavior in huge patient pool
To determine new therapeutic benefits or indications
Regulatory requirement: Structured Adverse Events reporting system Periodic Safety Update Reports (PSURs)
The PSURs are required to be submitted to DCGI – Once in every six months for the first two
years of the drug approval
Yearly once for the next two years
Then to be submitted annually.
The Periodic Safety Update Report (PSUR) is required as part of the FDA Post Marketing Drug Risk Assessment (PMDRA) program.
USFDA-quarterly reports during first 3 years, then annual reports
EMEA - Report should be submitted every 6 months for first 2 years, annually for next three years and then five yearly after the first renewal
Country: India Authority: Central Drug Standard
Control Organization (CDSCO) Head: Drug controller general of India
(DCGI)
The CDSCO, headed by the DCGI, is primarily responsible for coordinating the activities of the State Drugs Control Organization, formulating policies and ensuring uniform implementation of the Drugs and Cosmetics Act of 1940 (DC Act) and the Drugs and Cosmetics Rules of 1945 (DC Rules) throughout India.
Schedule Y: The legislative requirements of pharmacovigilance in India are guided by specifications of Schedule Y.
United States of America Authority: United States Food and Drug
administration (USFDA)
United Kingdom Authority: Medicines and Healthcare
products Regulatory Agency (MHRA)
European countries Authority: Evaluation agency for
European medicines (or) European medicines evaluation agency (EMEA)
Australia Authority: Therapeutic Goods
Administration (TGA)
Country: Canada Authority: Health Canada
PharmaMedical
Statistician
StatisticianOther
LifeSciences
TherapeuticsGuidelines
AndRegulations
Clinical Research Coordinator (CRC) or Clinical Trial Assistant (CTA)
Clinical Research Associate (CRA) Pharmacovigilance Specialist Clinical Data Associate Medical coder Medical Writer Regulatory Affairs or Medical Affairs Associate Literature Expert Medical Adviser or Medical Monitor (Medical
background) Biostatistician
JOB PROFILES
Questions???
Thank You
Recommended